title: Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability.
abstract: Stable gastric pentadecapeptide BPC 157 was suggested to link inflammatory bowel disease and multiple sclerosis, and thereby, shown to equally counteract the models of both of those diseases. For colitis, cysteamine (400 mg/kg intrarectally (1 ml/rat)) and colon-colon anastomosis (sacrifice at day 3, 5, 7, and 14) were used. BPC 157 (10 μg/kg, 10 ng/kg) was applied either intraperitoneally once time daily (first application immediately after surgery, last at 24 hours before sacrifice) or per-orally in drinking water (0.16 μg/ml/12 ml/day till the sacrifice) while controls simultaneously received an equivolume of saline (5 ml/kg) intraperitoneally or drinking water only (12 ml/day). A multiple sclerosis suited toxic rat model, cuprizone (compared with standard, a several times higher regimen, 2.5% of diet regimen + 1 g/kg intragastrically/day) was combined with BPC 157 (in drinking water 0.16 μg or 0.16 ng/ml/12 ml/day/rat + 10 μg or 10 ng/kg intragastrically/day) till the sacrifice at day 4. In general, the controls could not heal cysteamine colitis and colon-colon anastomosis. BPC 157 induced an efficient healing of both at the same time. Likewise, cuprizone-controls clearly exhibited an exaggerated and accelerated damaging process; nerve damage appeared in various brain areas, with most prominent damage in corpus callosum, laterodorsal thalamus, nucleus reunions, anterior horn motor neurons. BPC 157-cuprizone rats had consistently less nerve damage in all damaged areas, especially in those areas that otherwise were most affected. Consistently, BPC 157 counteracted cerebellar ataxia and impaired forelimb function. Thereby, this experimental evidence advocates BPC 157 in both inflammatory bowel disease and multiple sclerosis therapy.
authors.affiliation: Department of Pharmacology, Medical Faculty, University of Zagreb, Zagreb, Croatia. sikiric@mef.hr.
authors.forename: R
authors.initials: R
authors.lastname: Klicek
authors.forename: D
authors.initials: D
authors.lastname: Kolenc
authors.forename: J
authors.initials: J
authors.lastname: Suran
authors.forename: D
authors.initials: D
authors.lastname: Drmic
authors.forename: L
authors.initials: L
authors.lastname: Brcic
authors.forename: G
authors.initials: G
authors.lastname: Aralica
authors.forename: M
authors.initials: M
authors.lastname: Sever
authors.forename: J
authors.initials: J
authors.lastname: Holjevac
authors.forename: B
authors.initials: B
authors.lastname: Radic
authors.forename: T
authors.initials: T
authors.lastname: Turudic
authors.forename: A
authors.initials: A
authors.lastname: Kokot
authors.forename: L
authors.initials: L
authors.lastname: Patrlj
authors.forename: R
authors.initials: R
authors.lastname: Rucman
authors.forename: S
authors.initials: S
authors.lastname: Seiwerth
authors.forename: P
authors.initials: P
authors.lastname: Sikiric
mesh_terms: D000714:Anastomosis, Surgical; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001259:Ataxia / Q000188:drug therapy; D001522:Behavior, Animal / Q000187:drug effects; D001921:Brain / Q000473:pathology; D001930:Brain Injuries / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D003093:Colitis, Ulcerative / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D003106:Colon / Q000473:pathology / Q000601:surgery; D003471:Cuprizone; D003543:Cysteamine; D005552:Forelimb / Q000503:physiopathology; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D010446:Peptide Fragments / Q000494:pharmacology / Q000627:therapeutic use*; D011506:Proteins / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar
chemical_list: D000893:Anti-Inflammatory Agents; D000897:Anti-Ulcer Agents; D018696:Neuroprotective Agents; D010446:Peptide Fragments; D011506:Proteins; D003471:Cuprizone; D003543:Cysteamine; C083833:BPC 157